Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | EVP Operations | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table I · non-derivative | Direct | 6,000,000 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Exercise / conversion · Acquired 2,500,000 · Balance 6,000,000 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Exercise / conversion · Disposed 2,500,000 · Balance 0 F1: All of the stock options were fully vested and exercisable as of the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the stock options were fully vested and exercisable as of the transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:35 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionStock Options (right to buy) · Derivative | 2,500,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001493152-26-002062 · ownership.xml · derivative · entry 2 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the stock options were fully vested and exercisable as of the transaction date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:35 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionStock Options (right to buy) | 2,500,000 | $0.03 | $75,000.00 |
DisclosureSEC source: 0001493152-26-002062 · ownership.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2025 Filed Oct 4, 2025 01:58 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Salecommon stock | 800,000 | $0.62 | $499,200.00 |
DisclosureSEC source: 0001493152-25-016979 · ownership.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500,000 Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | SaleStock Options (right to buy) | 200,000 | $0.58 | $115,800.00 |
DisclosureSEC source: 0001641172-25-018593 · ownership.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300,000 Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:15 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionStock Options (right to buy) · Derivative | 2,500,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001641172-25-018199 · ownership.xml · derivative · entry 2 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 2,500,000 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the stock options were fully vested and exercisable as of the transaction date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:15 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionStock Options (right to buy) | 2,500,000 | $0.03 | $75,000.00 |
DisclosureSEC source: 0001641172-25-018199 · ownership.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 21:23 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | SaleCommon Stock | 333,932 | $0.51 | $170,305.32 |
DisclosureSEC source: 0001493152-24-042726 · ownership.xml · nonDerivative · entry 2 Plassche Douglas · CIK 0001600946 · SVP of Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 23, 2024 Filed Oct 28, 2024 21:23 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | SaleCommon Stock | 800,000 | $0.49 | $392,000.00 |
DisclosureSEC source: 0001493152-24-042726 · ownership.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · SVP of Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,932 Read SEC document |
| January 03, 2023 Filed Jun 26, 2023 16:46 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantOptions · Derivative | 7,500,000 | $0.03 Strike: $0.03 | $225,000.00 |
DisclosureSEC source: 0001600946-23-000001 · primary_doc.xml · derivative · entry 1 Plassche Douglas · CIK 0001600946 · Executive VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500,000 Underlying: Common Stock · 7,500,000 shares Expires 2033-01-03 F1 · shares: Options were awarded by the Board of Directions as part of Mr. Plassche's employment retention agreement. F2 · derivative.exercise_date: The options will best over a three-year period, commencing one year from the date of issuance. The first third will vest on January 3, 2024. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:24 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 71,739 | $0.09 | $6,284.34 |
DisclosureSEC source: 0001324222-20-000005 · primary_doc.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · SVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,932 Read SEC document |
| June 30, 2020 Filed Jul 6, 2020 15:38 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 574,597 | $0.09 | $49,989.94 |
DisclosureSEC source: 0001600946-20-000001 · primary_doc.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · SVP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,193 F1 · shares: Represents 2018 and 2019 salary shares Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 22:02 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 201,717 | $0.12 | $24,992.74 |
DisclosureSEC source: 0001053369-18-000005 · primary_doc.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · SVP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,596 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:46 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 110,849 | $0.23 | $24,996.45 |
DisclosureSEC source: 0001053369-17-000005 · primary_doc.xml · nonDerivative · entry 1 Plassche Douglas · CIK 0001600946 · SVP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,879 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.